Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Bionor

- PMLiVE

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Cuttsy + Cuttsy

- PMLiVE

Gilead’s New Drug Application for Yeztugo accepted by US FDA

The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention

- PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

- PMLiVE

Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

More than 100 people in the US were diagnosed with HIV every day in 2023

- PMLiVE

Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn

The companies will aim to discover new antibody-based therapeutics for cancer

- PMLiVE

Cultivating Interest in Infectious Disease Education at ID Week 2024

IDWeek starts tomorrow, October 16, and Medscape is bringing outcomes and education! We are excited to announce Medscape is presenting six posters that highlight the significant impact of our educational...

Medscape Education

- PMLiVE

Innovative Trials Announces New Charity Partnerships

Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

Innovative Trials

- PMLiVE

Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations

“I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...

Medscape Education

- PMLiVE

Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership

The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn

- PMLiVE

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

Genesis Research Group

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

New technique enables study of immune response to cancer using archived tissue samples

FUME-TCRseq was shown to successfully read formalin-fixed paraffin-embedded tissue samples

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links